Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism - Full Text View

Purpose

A study to determine the possibility of using far infrared radiation to treat Hyperparathyroidism.

Condition	Intervention	Phase
Hyperparathyroidism	Radiation: Far Infrared Radiation	Phase I

Drug Information available for:

Parathyroid

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Official Title:	Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.

Further study details as provided by GAAD Medical Research Institute Inc.:

Primary Outcome Measures:

The primary end point is to determine the therapeutic effects of far infrared radiation on Hyperparathyroidism. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Effect of far infrared radiation treatment on other immune deficiency diseases like thyroidism and diabetes [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment:	2
Study Start Date:	January 2007
Estimated Study Completion Date:	December 2008
Estimated Primary Completion Date:	August 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1	Radiation: Far Infrared Radiation Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.

Detailed Description:

Overactive parathyroid glands secrete an excess of parathyroid hormones, resulting in increased levels of calcium in the blood stream, which can lead to weakening of the bones and to kidney stones.

We are postulating that the non-invasive energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to stop the over secretion of the parathyroid hormones and normalize the body's metabolic functions.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Persons with parathyroid disease

Exclusion Criteria:

None

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00573573

Locations


Canada, Ontario
	The Centre for Incurable Diseases
	Toronto, Ontario, Canada, M4V 1L5

Sponsors and Collaborators

GAAD Medical Research Institute Inc.

Investigators


Study Director:	Francis Sam, M.D.	GAAD Medical Research Institute Inc.

Study Chair:	Kwasi Donyina, Ph.D.	GAAD Medical Research Institute Inc.

More Information

Responsible Party:	GAAD Medical Research Institute Inc. ( Dr. Kwasi Donyina/Founder and President )
Study ID Numbers:	GAAD-HT-CTP1
First Received:	December 12, 2007
Last Updated:	August 28, 2008
ClinicalTrials.gov Identifier:	NCT00573573
Health Authority:	Canada: Health Canada

Keywords provided by GAAD Medical Research Institute Inc.:

PRIMARY HYPERPARATHYROIDISM

PARATHYROID NEOPLASMS

SECONDARY HYPERPARATHYROIDISM

HYPOCALCEMIA

Study placed in the following topic categories:

Parathyroid Diseases

Parathyroid Neoplasms

Hyperparathyroidism, Secondary

Hypocalcemia

Hyperparathyroidism

Hyperparathyroidism, primary

Neoplasm Metastasis

Endocrine System Diseases

Endocrinopathy

Hyperparathyroidism, Primary

ClinicalTrials.gov processed this record on October 23, 2008

Sponsored by:	GAAD Medical Research Institute Inc.
Information provided by:	GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier:	NCT00573573